Skip Navigation

NHLBI Strategic Visioning

Community Update Button

NHLBI Clinical Trials

Trustworthy guidelines should be based on a systematic evidence review, developed by panel of multidisciplinary experts, provide a clear explanation of the logical relationships between alternative care options and health outcomes, and provide ratings of both the quality of evidence and the strength of the recommendations.

NHLBI Systematic Evidence Reviews in development.

Funding Opportunities

Inside NHLBI

Featured Fact Sheet

Afia Donkor, a Candian woman who once live with sickle cell disease.

“Feels Like a Cure”: Sickle Cell Patient Triumphs after Experimental Bone Marrow Transplant

In 2010, Afia Donkor, a young woman from Canada, struggled to walk a few blocks from her home to a subway station in Montreal on her way to the airport. Suitcase in hand, she moved at a snail’s pace as she experienced severe exhaustion due to a flare-up of her sickle cell disease. One step at a time, she finally made it, propelled by the hope of a new treatment that awaited her at the other end of her journey to the United States. Read full fact sheet...

View All Fact Sheets

On World Sickle Cell Day, an Invitation to the Community

Gary H. Gibbons, M.D.
June 19, 2015
Each June, World Sickle Cell Day offers NHLBI a chance to reflect on our ongoing commitment to improving the lives of those living with this devastating blood disorder. Sickle cell disease affects millions worldwide and about 90,000 to 100,000 people in the United States. NHLBI- and NIH-supported research has made significant advances that have helped extend the lives of those who have sickle cell disease. But we recognize much remains to be accomplished, such as enabling a generation of children with sickle cell disease to live without fear of suffering a stroke. Our efforts include not only seeking a more-widely available cure but engaging and enriching the community affected by this life-long condition.
View full message

View all Director's messages

Subscribe to receive "What's New" by email: